Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Curevo Vaccine announces closing of $26m Series A1 round
Curevo Vaccine CEO George Simeon said: “Completing this A1 round ahead of data from our Phase 2b trial of CRV-101 head-to-head against Shingrix is a meaningful demonstration of
Curevo Vaccine CEO George Simeon said: “Completing this A1 round ahead of data from our Phase 2b trial of CRV-101 head-to-head against Shingrix is a meaningful demonstration of
The financing round was co-led by ORI Capital, Longitude Capital and Decheng Capital. It has also seen participation from RA Capital Management, Acorn Bioventures, Malin Corporation, Ally Bridge
Nearly 1,600 people in England alone are expected to benefit from the immunotherapy drug. Previously, the drug was available for a small group of people with advanced TNBC
The new, oral formulation of CD/LD extended-release capsules, IPX203 features immediate-release granules and extended-release beads. Findings from the pivotal Phase III RISE-PD clinical trial showed that the extended-release
The collaboration will focus on discovering and developing nucleic acid-based immunotherapies for selected oncology targets using Harbour BioMed’s heavy chain only antibody discovery platform (HCAb). HCAb’s technology produces
This approval comes after European Commission gave its approval earlier this month. About 90% of children by the age of two get infected by RSV, which is a
Currently, the company is enrolling a Phase 1 trial analysing ITI-3000, a plasmid DNA (pDNA) vaccine targeting patients with MCC. MCC is a rare but aggressive form of
Under the deal terms, the company will provide funding for clinical development of its next-generation antibody-drug conjugate (ADC), NAV-001. The experimental ADC targets and kills tumour cells which
The double-blind, multicentre, placebo-controlled, randomised, dose-finding Phase II OCEAN(a)-DOSE study was designed for evaluating olpasiran’s tolerability, safety, as well as the optimal dose in atherosclerotic cardiovascular disease (ASCVD)
The new 1,500m2 facility will expand the company’s large-scale viral vectors production capabilities for vaccines and gene therapy. It has been designed to meet the increasing demand for